Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$306.81
Open:$307.12
Day's Low:$306.41
Day's High:$312.61
Bid / Ask:-
Market Cap:118.22B
Enterprise Value:128.96B
52-Week Range
52-Week Low:$267.00
52-Week High:$389.33
Current position in 52-week range
52w Low-52w High
50-Day Avg:$292.25
200-Day Avg:$323.54
Volume
Volume Today:2,588,205
Avg Volume (3m):2,703,820
Avg Volume (10d):3,010,520
52-Week Change:-15.39%
vs S&P 500, 52 weeks:-
Beta:0.77
Valuation Multiples
P/E (trailing):33.07
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
P/E (forward):19.04
PEG Ratio:1.44
Price / Book:5.04
Price / Sales (TTM):4.50
EV / Revenue:4.90
EV / EBITDA:17.17
Dividends
Current yield:1.15%
Annual Dividend Rate:$3.52
Dividend Trailing:$3.52
Yield Trailing:1.15%
5-Year Avg Yield:0.99%
Payout Ratio:37.49%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):26.30B
Gross Profit:17.28B
EBITDA:7.51B
Net Income (TTM):3.62B
Rev Growth (YoY):+7.60%
Earnings Growth (YoY):-11.70%
Quarterly earnings growth (YoY):-12.30%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$9.39
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.31
Revenue Per Share:$68.70
Cash Per Share:-
Book Value:$61.62
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:3.27B
Total Debt:15.43B
Net Debt (Debt - Cash):12.16B
Debt / Equity:65.79%
Current Ratio:2.18
Quick Ratio:1.07
Cash Flows
Operating Cash Flow:5.45B
Free Cash Flow (FCF):3.70B
FCF Yield (FCF / Market Cap):-
Enterprise Value:128.96B
EV / Revenue:4.90
EV / EBITDA:17.17
Profitability
ROE (Return on Equity):16.02%
ROA (Return on Assets):8.36%
P/E (trailing):33.07
P/E (forward):19.04
Price / Book:5.04
PEG Ratio:1.44
52-Week Change:-15.39%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$9.39
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 30, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.31
P/E (forward):19.04
PEG Ratio:1.44
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$68.70
Cash Per Share:-
Book Value:$61.62
Cash Flows (TTM)
Free Cash Flow:3.70B
Operating Cash Flow:5.45B
EBITDA:7.51B
Total Revenue (TTM):26.30B
Net Income (TTM):3.62B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:380,691,004
Float (free shares):345,522,769
Short interest (shares):5,700,373
Short % of float:-
Short Ratio (days to cover):2.15
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Stryker Corporation (SYK) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Stryker Corporation (SYK): Quantitative Analysis
Stryker Corporation (SYK) — Healthcare — Medical Devices. SYK is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, SYK has returned −10.9% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
SYK ranks 402 of 461 on today's multifactor score, and 50 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.16, ranked 154 of 468); its weakest is momentum (Z -0.98, ranked 429 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Stryker has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 after the close (SEC filings through Oct 29, 2026). SYK earnings dates and times, quarter by quarter →
What is Stryker's P/E ratio?
Stryker's P/E (price over earnings per share for the last twelve months) is 33.1 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Stryker is above its sector median. Healthcare stocks, company by company →
Where does Stryker rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Stryker ranks 402 of 461, and 50 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Stryker insiders bought or sold shares?
The latest open-market purchase of Stryker shares filed with the SEC (Form 4) was on Nov 22, 2022, by a director, for $4k. The latest sale was on Aug 21, 2026, by an officer, for $145k. In total, from August 2025 through Nov 3, 2026: 5 purchases and 15 sales by directors, officers and large shareholders. All SYK insider trades →
Does Stryker pay a dividend?
Yes. Its dividend yield is 1.15% at the Nov 3, 2026 close (annual dividend of $3.52 per share). The latest recorded ex-dividend date is Sep 30, 2026.
What sector is Stryker in, and which index?
Stryker is classified in the Healthcare sector (industry: Medical Devices), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.